Clinical
Trials
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
At BeiGene, we’re committed to bringing patients worldwide potential treatment options. We are currently recruiting clinical trials across areas including lymphoma, liver cancers, lung cancers, gastric cancers, breast cancers, and more.
-
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
Condition:
Tumor
Molecule:Sitravatinib
-
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma (ROSEWOOD)
Condition:
Lymphoma
Molecule:Zanubrutinib
-
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma
Condition:
Lymphoma
Molecule:Zanubrutinib
-
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gast…
Condition:
Gastric Cancer
Molecule:Sitravatinib + Tislelizumab
-
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.
Condition:
Advanced Solid Tumor
Molecule:Sitravatinib
-
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer
Condition:
Nasopharyngeal Cancer
Molecule:Tislelizumab
-
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)
Condition:
Leukemia, Lymphoma
Molecule:Zanubrutinib
-
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Condition:
MSI-H/dMMR Solid Tumors
Molecule:Tislelizumab
-
Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies
Condition:
Advanced Malignancies
Molecule:Tislelizumab + Pamiparib
-
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
Condition:
B-cell Malignancies
Molecule:Zanubrutinib
Clinical trials are an important part of our research and development efforts and help make possible access to safe and potentially life-saving treatments.
This list includes trials with the following recruitment statuses: recruiting, enrolling by invitation, study start-up, not yet recruiting, and active/not recruiting.